-transparent.png){kind=logo}
Biaryl amide glucagon receptor antagonists. 2004
Ravi Kurukulasuriya, and
Bryan K Sorensen, and
James T Link, and
Jyoti R Patel, and
Hwan-Soo Jae, and
Marty X Winn, and
Jeffrey R Rohde, and
Nelson D Grihalde, and
Chun W Lin, and
Christopher A Ogiela, and
Andrew L Adler, and
Christine A Collins
Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-6098, USA. ravi.kurukulasuriya@abbott.com
Biaryl amides derived from a reported series of ureas 1 were evaluated and found to be potent human glucagon receptor antagonists. The benzofuran analogue 6i was administered in Sprague-Dawley rats and blocked the effects of an exogenous glucagon challenge.
Related Publications
Ravi Kurukulasuriya, and
Bryan K Sorensen, and
James T Link, and
Jyoti R Patel, and
Hwan-Soo Jae, and
Marty X Winn, and
Jeffrey R Rohde, and
Nelson D Grihalde, and
Chun W Lin, and
Christopher A Ogiela, and
Andrew L Adler, and
Christine A Collins
July 2018,
Chemical biology & drug design,
Ravi Kurukulasuriya, and
Bryan K Sorensen, and
James T Link, and
Jyoti R Patel, and
Hwan-Soo Jae, and
Marty X Winn, and
Jeffrey R Rohde, and
Nelson D Grihalde, and
Chun W Lin, and
Christopher A Ogiela, and
Andrew L Adler, and
Christine A Collins
May 2006,
Bioorganic & medicinal chemistry letters,
Ravi Kurukulasuriya, and
Bryan K Sorensen, and
James T Link, and
Jyoti R Patel, and
Hwan-Soo Jae, and
Marty X Winn, and
Jeffrey R Rohde, and
Nelson D Grihalde, and
Chun W Lin, and
Christopher A Ogiela, and
Andrew L Adler, and
Christine A Collins
September 2001,
Bioorganic & medicinal chemistry letters,
Ravi Kurukulasuriya, and
Bryan K Sorensen, and
James T Link, and
Jyoti R Patel, and
Hwan-Soo Jae, and
Marty X Winn, and
Jeffrey R Rohde, and
Nelson D Grihalde, and
Chun W Lin, and
Christopher A Ogiela, and
Andrew L Adler, and
Christine A Collins
March 1999,
Bioorganic & medicinal chemistry letters,
Ravi Kurukulasuriya, and
Bryan K Sorensen, and
James T Link, and
Jyoti R Patel, and
Hwan-Soo Jae, and
Marty X Winn, and
Jeffrey R Rohde, and
Nelson D Grihalde, and
Chun W Lin, and
Christopher A Ogiela, and
Andrew L Adler, and
Christine A Collins
December 2005,
Bioorganic & medicinal chemistry letters,
Ravi Kurukulasuriya, and
Bryan K Sorensen, and
James T Link, and
Jyoti R Patel, and
Hwan-Soo Jae, and
Marty X Winn, and
Jeffrey R Rohde, and
Nelson D Grihalde, and
Chun W Lin, and
Christopher A Ogiela, and
Andrew L Adler, and
Christine A Collins
June 2016,
Bioorganic & medicinal chemistry letters,
Ravi Kurukulasuriya, and
Bryan K Sorensen, and
James T Link, and
Jyoti R Patel, and
Hwan-Soo Jae, and
Marty X Winn, and
Jeffrey R Rohde, and
Nelson D Grihalde, and
Chun W Lin, and
Christopher A Ogiela, and
Andrew L Adler, and
Christine A Collins
July 2006,
Bioorganic & medicinal chemistry letters,
Ravi Kurukulasuriya, and
Bryan K Sorensen, and
James T Link, and
Jyoti R Patel, and
Hwan-Soo Jae, and
Marty X Winn, and
Jeffrey R Rohde, and
Nelson D Grihalde, and
Chun W Lin, and
Christopher A Ogiela, and
Andrew L Adler, and
Christine A Collins
March 2007,
Bioorganic & medicinal chemistry letters,
Ravi Kurukulasuriya, and
Bryan K Sorensen, and
James T Link, and
Jyoti R Patel, and
Hwan-Soo Jae, and
Marty X Winn, and
Jeffrey R Rohde, and
Nelson D Grihalde, and
Chun W Lin, and
Christopher A Ogiela, and
Andrew L Adler, and
Christine A Collins
November 1985,
Journal of medicinal chemistry,
Ravi Kurukulasuriya, and
Bryan K Sorensen, and
James T Link, and
Jyoti R Patel, and
Hwan-Soo Jae, and
Marty X Winn, and
Jeffrey R Rohde, and
Nelson D Grihalde, and
Chun W Lin, and
Christopher A Ogiela, and
Andrew L Adler, and
Christine A Collins
September 1999,
Current pharmaceutical design,
